Annual Report FY 2025-26

August 20, 2026 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001. Scrip Code: 540737 Dear Sir / Ma’am, Subject: Annual Report – 2026 & Notice of 31st Annual General Meeting. With reference to the captioned subject, we inform that 31st Annual General Meeting (“AGM”) of the Company shall be held on Saturday, September 12, 2026 at 11.30 a.m. through Video Conferencing (“VC”)/Other Audio-Visual Means (“OAVM”), in accordance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. Pursuant to regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith Annual Report for the FY 2025-26 and the Notice of 31st AGM. The said reports are being sent to the shareholders through email and have been uploaded on the “investors” section of the website of the Company at: www.ganeshremedies.com The “cut-off date” for determining eligibility of shareholders for remote e-voting/e-voting at AGM and for attending AGM is fixed as Saturday, September 05, 2026. The remote e-voting period shall commence from Wednesday, September 09, 2026 at 9.00 a.m. and end on Friday, September 11, 2026 at 5.00 p.m. The detailed instruction with regard to the remote e-voting/e-voting at AGM and procedure for attending AGM is provided in the notice of AGM which are being sent to shareholders and submitted to stock exchanges. The procedure for attending the AGM is provided in the Notice of AGM. Kindly take the same on your record. Thanking you, Yours faithfully, For Shree Ganesh Remedies Limited Aditya Patel Company Secretary and Compliance Officer Investing Ahead of the Curve SHREE GANESH REMEDIES LIMITED ANNUAL REPORT 2025-26 WEIVER CIGETARTS Progress in speciality chemistry is rarely immediate. The molecules that matter most are complex, niche DISCLAIMER In this This document contains and technically demanding, and the capability to make statements about expected Report - them is built long before the market rewards it. This has future events and financials STRATEGIC REVIEW of Shree Ganesh Remedies shaped how the Company thinks and how it invests. Limited, which are forward- 02 About the Company looking. By their nature, forward- looking statements 04 Our Journey require the Company to make assumptions and are 06 Chairman and Managing Director’s Message subject to inherent risks 08 Q&A with Management FY26 was a year of deliberate It means accepting that returns are and uncertainties. There is groundwork. The Company chose realised over a multi-year horizon, that a significant risk that these 10 Our Offerings to strengthen the foundations of the some costs are incurred well before assumptions, predictions 14 Our Evolving Business Model business at a time when the operating the revenue that justifies them, and and other forward-looking statements may not prove 16 State-of-the-Art Infrastructure environment remained demanding, that headline growth in any single year to be accurate. Readers believing that the most durable may not reflect the strength being built are cautioned not to place 18 Research and Development value is created by preparing for beneath it. The Company makes this undue reliance on forward 20 Our Presence looking statements as a opportunities before they arrive rather choice knowingly, because the work number of factors could 22 Key Performance Indicators than reacting once they do. Capacity it pursues is the kind that only a small cause assumptions, actual 24 Our Strengths was commissioned, a new pilot facility number of manufacturers anywhere future results and events to differ materially from 26 Corporate Social Responsibility with flow chemistry was brought can undertake. those expressed in the into operation, and CRAMS projects forward-looking statements. 28 Management Discussion and Analysis advanced from pilot to commercial The result is a business that is Accordingly, this document is structurally and fundamentally trials. These are investments whose full subject to the disclaimer and stronger than it was a year ago, with a qualified in its entirety by the return lies ahead. wider pipeline, deeper chemistry and assumptions, qualifications and risk factors referred to in STATUTORY REPORTS Investing ahead of the greater capacity in place for the years the Management Discussion curve calls for conviction that follow. As demand recovers and and Analysis section of this 42 Corporate Information and patience. new opportunities take shape, the Annual Report. 43 Notice Company intends to be ready, having invested ahead of the curve. 55 Director’s report 71 Corporate governance report FINANCIAL STATEMENTS 89 Standalone Financial Statements 140 Consolidated Financial Statements FIND OUT MORE ON Investing Ahead www.ganeshremedies.com of the Curve 02 03 SHREE GANESH REMEDIES LIMITED ANNUAL REPORT 2025-26 WEIVER CIGETARTS ABOUT THE COMPANY Two Decades of Mastery in Complex Chemistry OUR VALUES Shree Ganesh Remedies Limited is a From its manufacturing base at Ankleshwar in Gujarat, the Company serves customers across more than People Customer INDUSTRIES SERVED chemistry-driven manufacturer of 20 countries, supplying intermediates and speciality pharmaceutical intermediates and molecules to the pharmaceutical, agrochemical, polymer First Delight Human and speciality and fine chemicals, with a track and electronics industries. Its work centres on mastering Veterinary Health record spanning more than two decades. difficult chemistries and translating them into dependable, Connect, care, Delivering exceptional commercial-scale production for demanding global clients. The Company is built on a single, hard- development experience Agrochemicals Over time, the Company has steadily moved up the value won strength: the ability to execute chain towards patented, customer-specific speciality Polymers complex, multi-step chemistries that few molecules and contract manufacturing engagements, Team Work Quality manufacturers in India can deliver. while continuing to serve its established intermediates Electronics portfolio. Sustained investment in R&D, pilot infrastructure Achieving more Continuous improvement and new manufacturing capacity now widens the platform together and innovation on which the next phase of growth will be built. 20+ 40 37% 20+ 2 63% Years of expertise in R&D and process Contribution from Countries served Focused business Contribution from complex chemistry development team Speciality and Fine worldwide verticals Pharmaceutical members Chemicals for FY26 Intermediates for FY26 c Business a m Verticals m Patented and client- Custom intermediates for e specific molecules complex, off-patent and a h requiring advanced, generic drug molecules, C multi-chemistry where stringent process capability, developed in control and advanced e partnership with global chemistry are essential. i n majors. The Company’s Now below 65% of a i growth engine. revenue. l & et i l e ai c se t a i d WEIVER CIGETARTS 04 05 OUR JOURNEY PHASES OF GROWTH A Journey of The Company’s growth has unfolded in deliberate phases, each adding the skills, Incorporation & Early Growth 1992–2017 Deliberate infrastructure and relationships needed to FROM THEN TO NOW take on more complex work. From a single A single facility grew into a listed manufacturing facility to a recognised company. The period built the Progress A single Two sites at partner for global majors, the journey reflects Company’s core chemistry skills, early manufacturing Ankleshwar and a consistent move towards higher-value, ISO certifications and an expanding facility one site at Dahej export base, recognition from the technically demanding chemistry. MSME sector and, in 2017, a listing on the BSE SME platform. Generic Custom, multi- pharmaceutical chemistry molecules Rapid Scale-Up intermediates for global majors 2018–2025 1992 2004 2005 2010 Capacity and capability expanded A regional, in step. New manuf [Showing first 8,000 characters — download PDF for full document]